IDH1 and leukemia: Similar to IDH1/2 mutations, mutations in and the promoter hypermethylation of TET2 have been confirmed in leukaemias, myelodysplastic syndrome, myeloproliferative neoplasms and low-grade diffuse gliomas [4, 6, 10].